National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Niraparib (Zejula®) which is indicated as monotherapy for maintenance treatment of adult patients with platinum-sensitive, relapsed, high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in response (complete response [CR] or partial response [PR]) to platinum-based chemotherapy.

NCPE Assessment Process Ongoing
Rapid review commissioned 01/06/2018
Rapid review completed 21/06/2018
Rapid Review outcome A full pharmacoeconomic assessment is recommended to assess the clinical effectiveness and cost effectiveness of niraparib compared with the current standard of care
Full pharmacoeconomic assessment commissioned by HSE 27/06/2018
Pre submission consultation with Applicant 14/08/2018
Submission received from Applicant 09/01/2019
Current status HTA assessment ongoing